# Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

> **NCT03048877** · PHASE3 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 118 (estimated)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Apatinib Oral Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03048877
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2020-03-25
- **Final completion:** 2023-12-31
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03048877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03048877, "Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03048877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*